Completed PHASE4 INTERVENTIONAL 3-arm NCT00413790

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

A 3-Way Cross-Over, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Pharmacologic Effects of a 7-Day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older

Sponsor: Novartis

Conditions Healthy

Interventions Darifenacin Placebo Tolterodine

Updated 5 times since 2017 Last updated: Jan 14, 2008 Started: Nov 30, 2006 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Healthy and is currently completed. Novartis leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Procter and Gamble

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Buffalo, United States , Dallas, United States , Hackensack, United States , Jacksonville, United States , Jupiter, United States , Madisonville, United States , Overland Park, United States , San Diego, United States , Scottsdale, United States and 2 more locations